TRPM2 and non-small cell lung carcinoma: In our effort to understand the molecular mechanisms by which osimertinib exerts its therapeutic effect in sensitive EGFRm NSCLC cells/tumors, we identified that TRPM2 was ranked top among a few TRP genes whose expression was significantly inhibited by osimertinib in both PC‐9 and HCC827 cell lines based on analysis of our RNA sequencing (RNA‐seq) data that compared mRNA alterations between DMSO‐ and osimertinib‐treated PC‐9 or HCC827 cells[18] (Figure 1A).